Pharmaceutical

Fulcrum and CAMP4 to develop rare blood disorder therapies

Fulcrum Therapeutics has signed a licence agreement with CAMP4 Therapeutics to develop new therapies to treat Diamond-Blackfan anaemia.

Jul 11, 2023 - 20:00
Fulcrum and CAMP4 to develop rare blood disorder therapies
Fulcrum Therapeutics has signed a licence agreement with CAMP4 Therapeutics to develop new therapies to treat Diamond-Blackfan anaemia.
Read the original article

Tags:

Previous Article

Iovance looks to advance its non-small cell lung cancer therapy

Next Article

Astellas licenses 4DMT’s AAV vector for ophthalmic targets

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GoodRx hires former tech exec as CEO, Amazon shutters Halo, and Teladoc beats expectations

GoodRx hires former tech exec as CEO, Amazon shutters H...

Apr 27, 2023

STAT+: European companies outline opposition to proposed overhaul of pharma policy

STAT+: European companies outline opposition to propose...

Jun 22, 2023

Tevogen Bio partners Microsoft for HPV treatment

Tevogen Bio partners Microsoft for HPV treatment

Nov 7, 2024